RNA analysis of tape strips to rule out melanoma in lesions clinically assessed as cutaneous malignant melanoma: A diagnostic study

• Published in: Journal of the American Academy of Dermatology Vol. 89; no. 3; pp. 537 - 543
• Main Authors: Heerfordt, Ida M., Philipsen, Peter A., Andersen, Jeppe D., Langhans, Linnea, Schmidt, Grethe, Morling, Niels, Wulf, Hans Christian
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.09.2023
• Subjects: Antigens, Neoplasm; COVID-19; COVID-19 Testing; diagnostic tool; gene expression; Humans; melanoma; Melanoma - diagnosis; Melanoma - genetics; Melanoma - pathology; Melanoma, Cutaneous Malignant; nevi; Nevus - diagnosis; Nevus - genetics; noninvasive; PRAME; RNA; Skin Neoplasms - diagnosis; Skin Neoplasms - genetics; Skin Neoplasms - surgery; CMM; BCC; PLA; RNA; SRC; melanoma; Ct; noninvasive; diagnostic tool; KIT; nevi; PRAME; gene expression
• ISSN: 0190-9622; 1097-6787
• DOI: 10.1016/j.jaad.2023.05.030

Distinguishing cutaneous malignant melanoma (CMM) from nevi can be clinically challenging. Suspicious lesions are therefore excised, resulting in many benign lesions being removed surgically to find 1 CMM. It has been proposed to use tape strip derived ribonucleic acid (RNA) to distinguish CMM from nevi. To develop this technique further and validate if RNA profiles can rule out CMM in clinically suspicious lesions with 100% sensitivity. Before surgical excision, 200 lesions clinically assessed as CMM were tape stripped. Expression levels of 11 genes on the tapes were investigated by RNA measurement and used in a rule-out test. Histopathology showed that 73 CMMs and 127 non-CMMs were included. Our test correctly identified all CMMs (100% sensitivity) based on the expression levels of 2 oncogenes, PRAME and KIT, relative to a housekeeping gene. Patient age and sample storage time were also significant. Simultaneously, our test correctly excluded CMM in 32% of non-CMM lesions (32% specificity). Our sample contained a very high proportion of CMMs, perhaps due to inclusion during COVID-19 shutdown. Validation in a separate trial must be performed. Our results demonstrate that the technique can reduce removal of benign lesions by one-third without overlooking any CMMs.